6 results about "Ischemic brain" patented technology

This invention relates to the fields of pharmaceuticals and nanomedicine, specifically disclosing the preparation of a dual-targeting liposome drug delivery system and its application in stroke. The dual-targeting liposome drug delivery system comprises neutrophils, artemisinin, edaravone, and liposomes. The liposomes co-load artemisinin and edaravone, and their surfaces are modified with sialic acid derivatives and phosphatidylserine to form liposome nanomedicines. The neutrophils act as carriers, transporting the drug across the brain border (BBB) ​​and targeting it to the ischemic brain region. This dual-targeting strategy achieves precise two-stage drug delivery to the ischemic brain region. This delivery system can inhibit NLRP3 inflammasome activation, reduce pyroptosis, and promote microglial polarization towards the M2 anti-inflammatory phenotype, thereby effectively treating cerebral ischemia-reperfusion injury or ischemic stroke.

This invention discloses a brain-targeting neutrophil membrane-encapsulated tanshinone IIa PLGA nanoparticle formulation, its preparation method, and its uses. The brain-targeting tanshinone IIa nanoparticle formulation, Neu-Tan-IIa@PLGA, is characterized by comprising a PLGA-loaded tanshinone IIa nanoparticle core (Tan-IIa@PLGA) and an outer neutrophil membrane coating. This invention effectively overcomes the problems of poor water solubility, low oral bioavailability, and difficulty in crossing the blood-brain barrier associated with tanshinone IIa. This invention provides a tanshinone IIa with strong targeting and high drug stability, enabling delivery to lesions in ischemic brain regions and improving the safety and efficacy of stroke treatment.

This invention provides a drug delivery system and its application based on brain microvascular endothelial cells, comprising stimulated brain microvascular endothelial cells, wherein the stimulation is performed by culturing in a culture system containing supernatant of brain microvascular endothelial cells cultured under glucose and oxygen deprivation. This invention solves the problems of targeting and timeliness in treating blood-brain barrier damage after ischemic stroke under current technologies. It can regulate the BBB while supporting its function and structure, maintaining and repairing BBB function after reperfusion, thus improving the prognosis of stroke treatment. The cell preparations in this invention are widely available and easily obtained, and can rapidly repair the blood-brain barrier. Furthermore, the cell preparations in this invention can target ischemic brain sites and can be administered via simple intravenous injection, facilitating clinical operation.

The invention relates to systems and methods for predicting ischemic brain tissue fate from multi-phase CT-angiography. More specifically, systems and methods are provided that enable meaningful prediction of core, penumbra and perfusion from mCTA images using software that has been trained via machine learning to interpret mCTA images.

The application relates to application of Danshensu borneol ester related substances in treatment of ischemic brain and cardiovascular diseases. In particular, the application relates to use of Danshensu borneol ester isomers and derivatives thereof in preparation of medicines for preventing and treating ischemic cerebrovascular diseases and cardiovascular diseases, and belongs to the technical field of medicines.

The application discloses application of sh-SLK in preparation of a preparation for relieving cerebral ischemia-reperfusion injury, and relates to the technical field of gene targeting drugs. An effective active component of the preparation comprises short hairpin RNA sh-SLK capable of targeting and specifically silencing STE20-like kinase gene expression. The preparation is loaded in a recombinant virus carrier, and is formulated into a lateral cerebral ventricle injection dosage form; the preparation is delivered to brain tissues through a brain stereotactic technique, so that high-efficiency expression of sh-SLK is established in ischemic brain tissues, and then the activity of SLK is specifically inhibited.